The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

E. S. Molho, S. A. Factor, W. J. Weiner, J. R. Sanchez-Ramos, C. Singer, L. Shulman, D. Brown, C. Sheldon

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydrochloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in 'off' time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.

Original languageEnglish (US)
Pages (from-to)225-230
Number of pages6
JournalJournal of Neural Transmission, Supplement
Issue number45
StatePublished - Dec 11 1995
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease'. Together they form a unique fingerprint.

Cite this